SalaryGuide
AboutPricingFor Employers

Marketing jobs

8 marketing jobs

Gilead Sciences logo
3 weeks ago

Executive Director, Global Strategic Marketing – Early Inflammation Pipeline and Strategy, Commercial Team Lead (CTL)

Gilead Sciences

Foster City, CA (On-site)Full time$281K/yr – $364K/yr
Gilead Sciences logo
5 weeks ago

Executive Director, Global Marketing – HIV & Emerging Viruses

Gilead Sciences

Foster City, CA (Unknown)Full time$281K/yr – $364K/yr
Gilead Sciences logo
2 months ago

Director, Programmatic Media Strategy

Gilead Sciences

Parsippany, NJ (Hybrid)Full time$206K/yr – $266K/yr
Gilead Sciences logo
3 months ago

Director, Marketing Sciences - Integrated Insights

Gilead Sciences

Foster City, CA (Hybrid)Full time$226K/yr – $293K/yr
Gilead Sciences logo
4 months ago

Senior Product Manager, (HCP) Healthcare Practitioner Marketing, Oncology

Gilead Sciences

Foster City, CA (Hybrid)Full time$154K/yr – $219K/yr
Gilead Sciences logo
4 months ago

Director DTC, Marketing - HIV Prevention

Gilead Sciences

Foster City, CA (Hybrid)Full time$226K/yr – $293K/yr
Gilead Sciences logo
4 months ago

Director HCP Marketing Lead - HIV Prevention

Gilead Sciences

Foster City, CA (Hybrid)Full time$226K/yr – $293K/yr
Gilead Sciences logo
4 months ago

Director, HIV Treatment Marketing (DTP)

Gilead Sciences

Foster City, CA (Hybrid)Full time$226K/yr – $293K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

8 jobs
Gilead Sciences logo

Executive Director, Global Strategic Marketing – Early Inflammation Pipeline and Strategy, Commercial Team Lead (CTL)

Gilead Sciences

Foster City, CA (On-site)

$281K/yr - $364K/yrIn-houseFull-timeSenior level
3 weeks ago
Gilead Sciences logo

Executive Director, Global Marketing – HIV & Emerging Viruses

Gilead Sciences

Foster City, CA (Unknown)

$281K/yr - $364K/yrIn-houseFull-timeSenior level14+ years exp.
5 weeks ago
Gilead Sciences logo

Director, Programmatic Media Strategy

Gilead Sciences

Parsippany, NJ (Hybrid)

$206K/yr - $266K/yrIn-houseFull-timeDirector/executive10+ years exp.
2 months ago
Gilead Sciences logo

Director, Marketing Sciences - Integrated Insights

Gilead Sciences

Foster City, CA (Hybrid)

$226K/yr - $293K/yrIn-houseFull-timeDirector/executive12+ years exp.
3 months ago
Gilead Sciences logo

Senior Product Manager, (HCP) Healthcare Practitioner Marketing, Oncology

Gilead Sciences

Foster City, CA (Hybrid)

$154K/yr - $219K/yrIn-houseFull-timeSenior level
4 months ago
Gilead Sciences logo

Director DTC, Marketing - HIV Prevention

Gilead Sciences

Foster City, CA (Hybrid)

$226K/yr - $293K/yrIn-houseFull-timeDirector/executive12+ years exp.
4 months ago
Gilead Sciences logo

Director HCP Marketing Lead - HIV Prevention

Gilead Sciences

Foster City, CA (Hybrid)

$226K/yr - $293K/yrIn-houseFull-timeDirector/executive
4 months ago
Gilead Sciences logo

Director, HIV Treatment Marketing (DTP)

Gilead Sciences

Foster City, CA (Hybrid)

$226K/yr - $293K/yrIn-houseFull-timeDirector/executive
4 months ago
Gilead Sciences logo
Gilead Sciences

Executive Director, Global Strategic Marketing – Early Inflammation Pipeline and Strategy, Commercial Team Lead (CTL)

Foster City, CA (On-site)

$281K/yr – $364K/yrSenior LevelFull time

Posted 3 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own global early inflammation commercialization from strategy to launch, coordinating cross-functional teams and a select set of markets to maximize value and patient access.

  • Own the global strategic vision and cross-functional eCT to align with market, regulatory, and payer needs.
  • Partner with key markets to shape global strategies and coordinate clinical/regulatory planning.
  • Drive global brand development and market insights to differentiate and address unmet needs.

Job Description

  • Develop and execute the commercial strategic vision across Gilead’s early inflammation pipeline, balancing near-term and long-term priorities.
  • Represent global commercial on a Project Strategy Team and help shape clinical / regulatory strategy and planning in close partnership with cross-functional colleagues.
  • Establish and lead a cross functional global, early commercial team (eCT) and build integrated global strategies that meet global market, regulatory and payer needs as the pipeline assets advance toward registration, approval and launch.
  • Create strong and close working relationship with a few key Gilead markets, including ex-US markets, with whom you will partner for the development of global commercial strategies.
  • Develop the global brand profile and key marketing deliverables, including global brand vision and value proposition, accounting for competitive landscape and potential to differentiate competitively.
  • Conduct strategic marketing activities including market and competitive research and product positioning in close collaboration with cross-commercial disciplines.
  • Identify actionable insights based on market research and ensure that the product / brand addresses unmet need areas.
  • Your ultimate benchmark will be the successful development and execution of global commercial strategies that maximizes the overall value of our assets, while ensuring patient access across the product lifecycle.
Gilead Sciences logo

Gilead Sciences

3.8 Glassdoor

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives.Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Founded in 1987
San Mateo, California, USA
15K employees (773 in marketing)
www.gilead.com
74% recommend to a friend
80% CEO approval

Traffic Signals

Monthly Visitors
651.4K
Traffic Source Mix
Search
32.1%
Direct
49.6%
Referral
16.3%
Social
0.9%
Paid
0.9%

Headcount Trend

Current headcount: ~14.6K

Marketing Team

Marketing Team Size
617 (4% of company)
Median Career Experience
17 years
Median Tenure
4.3 years
Marketing Roles Posted (Last 30 Days)
6

People

HR / Recruitment

Carla Arzuaga Sheppard
Carla Arzuaga Sheppard
Director, Clinical Trials Recruitment - Digital Marketing & Referral Management
At the company for 3 years 3 months
Melissa Pappion
Melissa Pappion
Associate Director, Digital Marketing & Recruitment
At the company for 3 years 3 months

Marketing Leadership

Brenna Deck Mittel
Brenna Deck Mittel
Senior Director, US HIV Treatment Marketing
At the company for 10 months
Emily Cosse
Emily Cosse
Senior Director, HIV Prevention - Customer Experience Marketing
At the company for 11 years
Lauren Breslin
Director, US Oncology Marketing
At the company for 8 years 6 months
Eunhee So
Eunhee So
Director, Social Marketing
At the company for 2 years 10 months

Funding

Total Funding
$4.4B
Last Raise
$3.5M
Post IPO Debt, 1 years ago

Funding History

  • Nov 2024
    Post IPO Debt • $3.5M
  • Feb 2024
    Post IPO Equity • $210M
  • Sep 2023
    Post IPO Debt • $2B

Recent News

Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates
Dec 7, 2025 • Yahoo Finance
Gilead Sciences: About To Break Out (NASDAQ:GILD)
Nov 25, 2025 • Seeking Alpha
Gilead scoops up a preclinical cancer program
Nov 25, 2025 • BioPharma Dive
Gilead abruptly parts ways with general counsel—Chutes & Ladders
Nov 21, 2025 • Fierce Biotech
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Nov 20, 2025 • Yahoo Finance
Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets
Nov 19, 2025 • Yahoo Finance
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV-1 treatment meets primary endpoint in Phase 3 ARTISTRY-1 trial
Nov 13, 2025 • European AIDS Treatment Group
Assessing Gilead After 34% Rally and Recent Pharmaceutical Partnerships
Nov 12, 2025 • Yahoo Finance
How Recent Developments Are Shaping the Gilead Sciences Investment Story
Nov 8, 2025 • Yahoo Finance
Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions
Nov 5, 2025 • Yahoo Finance
Gilead Sciences to Present at Upcoming Investor Conferences
Nov 4, 2025 • Business Wire
Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround
Oct 31, 2025 • Yahoo Finance
Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales
Oct 31, 2025 • Fierce Pharma
Gilead Sciences Announces Third Quarter 2025 Financial Results
Oct 30, 2025 • Business Wire
Gilead ends phase 1 trial after settling on twice-yearly treatment partner for lenacapavir
Oct 30, 2025 • Fierce Biotech
Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations
Oct 30, 2025 • Yahoo Finance
Gilead posts higher profit on demand for HIV drugs, but overall sales dip
Oct 30, 2025 • Reuters
Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)
Oct 29, 2025 • Yahoo Finance
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
Oct 28, 2025 • Yahoo Finance
Gilead Sciences Stock Forecast: Where Analysts See the Stock Going by 2027
Oct 25, 2025 • TIKR.com
Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value
Oct 23, 2025 • Yahoo Finance
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
Oct 22, 2025 • Yahoo Finance
Gilead Sciences stock rating reiterated by RBC amid HIV drug setback
Oct 22, 2025 • Investing.com
Gilead Sciences Shows Market Leadership With Jump To 83 RS Rating
Oct 20, 2025 • Investor's Business Daily
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
Oct 18, 2025 • Seeking Alpha
A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results
Oct 17, 2025 • Yahoo Finance
Gilead, Roche latest to tap Chinese firms for drug development
Oct 17, 2025 • FirstWord Pharma
Gilead presents new HIV research data at EACS 2025 – driving scientific innovation in treatment and prevention
Oct 15, 2025 • European AIDS Treatment Group
Gilead to present data on potential first weekly oral treatment for HIV
Oct 15, 2025 • Clinical Trials Arena
How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline
Oct 11, 2025 • Yahoo Finance
Gilead: Incorporating Longer Biktarvy Runway
Oct 10, 2025 • Morningstar
A Look Inside Gilead's Inflammation Pipeline
Oct 9, 2025 • Gilead Sciences
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Oct 9, 2025 • Business Wire
Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning
Oct 8, 2025 • Yahoo Finance
Gilead inks trio of Biktarvy patent settlements, waylaying US copycats until 2036
Oct 7, 2025 • Fierce Pharma
Case overview, Gilead Sciences v Meritain Health, et al
Oct 4, 2025 • Partnership for Safe Medicines
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Oct 3, 2025 • Yahoo Finance
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Oct 2, 2025 • Yahoo Finance
Gilead Oncology Grantee Provides Practical Support for Patients Undergoing Breast Cancer Treatment
Oct 1, 2025 • Gilead Sciences
What Do Analysts Think About Gilead Sciences (GILD)?
Sep 30, 2025 • Yahoo Finance
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
Sep 29, 2025 • PR Newswire
Gilead pumps up virology pipeline with drug transporter deal
Sep 29, 2025 • Fierce Biotech
Morgan Stanley Maintains Buy on Gilead Sciences (GILD)
Sep 28, 2025 • Yahoo Finance
Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum
Sep 26, 2025 • Yahoo Finance
Gilead Foundation awards $6.5m in grants to support STEM education
Sep 26, 2025 • Pharmafile
JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating
Sep 26, 2025 • Yahoo Finance
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
Sep 26, 2025 • BioSpace
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Sep 25, 2025 • Yahoo Finance
Gilead drug deal opens door for $40-a-year generic version of groundbreaking HIV prevention overseas
Sep 25, 2025 • Seattle TechFlash
Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category
Sep 25, 2025 • Yahoo Finance
Bill Clinton calls out aid cuts, political unrest, and more at the Clinton Global Initiative
Sep 25, 2025 • Fast Company
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
Sep 24, 2025 • Yahoo Finance
Florida AG announces $3M settlement with Gilead Sciences over improper HIV drug promotion
Sep 24, 2025 • WPEC
Philanthropies Strike a Promising Deal to Turn Back H.I.V.
Sep 24, 2025 • NYT > Business
Lupin gets tentative nod from USFDA for generic HIV treatment drug
Sep 24, 2025 • IndiaTimes
STAT+: Global health groups push to make cheap generic versions of an HIV prevention drug sold by Gilead
Sep 24, 2025 • STAT
Lupin gets tentative nod from USFDA for generic HIV treatment drug
Sep 24, 2025 • Business Standard India
Zimbabwe to Roll Out Breakthrough HIV Prevention Drug
Sep 24, 2025 • AllAfrica.com
Activists demand $40-a-year generic PrEP
Sep 24, 2025 • Pharma Letter
Child mortality at risk of rising in 2025 for first time this century: Gates Foundation
Sep 24, 2025 • semafor.com
Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More (NASDAQ:GILD)
Sep 23, 2025 • Seeking Alpha
Gilead Sciences Combats $431 billion Pharmaceutical Fraud Threat with Neo4j Graph Analytics
Sep 23, 2025 • Neo4j
Did Gilead's (GILD) $32 Billion AI Bet Just Transform Its Innovation and Global Health Narrative?
Sep 22, 2025 • Yahoo Finance
Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030
Sep 21, 2025 • Yahoo Finance
STAT+: CDC recommends new Gilead HIV prevention drug, prompting advocates to push CVS for coverage
Sep 19, 2025 • STAT
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Sep 18, 2025 • Yahoo Finance
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Sep 18, 2025 • BioSpace
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
Sep 18, 2025 • Morningstar.com
Moody’s affirms Gilead’s A3 rating, revises outlook to positive
Sep 18, 2025 • Investing.com
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
Sep 18, 2025 • BioSpace
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
Sep 18, 2025 • Fangzhou Inc.
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
Sep 18, 2025 • PR Newswire
Nurix Therapeutics presents data from GS-6791
Sep 17, 2025 • thefly.com
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Sep 17, 2025 • Nurix Therapeutics, Inc.
Namibia: Trump Cuts Leave 4,000 Namibian Health Workers Facing the Sack
Sep 17, 2025 • AllAfrica.com
Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT
Sep 16, 2025 • Yahoo Finance
Global biotech leaders Amgen and Gilead announcing expansions in California, the #1 state for life sciences
Sep 15, 2025 • CA.gov
Gilead Sciences stock price target raised to $143 from $136 at Rothschild Redburn
Sep 12, 2025 • Investing.com
Gilead beats whistleblower lawsuit over hepatitis C drugs
Sep 12, 2025 • Reuters
Gilead Sciences Commits to Veeva Vault CRM
Sep 10, 2025 • Contract Pharma
Gilead Sciences Commits to Veeva Vault CRM
Sep 10, 2025 • PR Newswire
Gilead Price Hikes Screw ADAP Programs, HIV Patients--AHF Protest
Sep 9, 2025 • AIDS Healthcare Foundation
Xilio starts phase 2 trial for XTX301, hits $17.5M milestone in Gilead license deal
Sep 9, 2025 • MarketScreener
Transcript : Gilead Sciences, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 10
Sep 9, 2025 • MarketScreener
Gilead Sciences says remdesivir-copy patent in UPC action worth €20 million
Sep 8, 2025 • IAM Patent
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
Sep 8, 2025 • Business Wire
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
Sep 8, 2025 • PR Newswire
The Pharma Letter M&A roundup - August 2025
Sep 8, 2025 • Pharma Letter
Australia Acute Respiratory Distress Syndrome Market Analysis 2025-2033 | Disease Burden, Rising ICU Admissions, and Advancements in Medical Technology Drive ARDS Growth - ResearchAndMarkets.com
Sep 8, 2025 • Business Wire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Sep 8, 2025 • PR Newswire UK
WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.
Sep 8, 2025 • PR Newswire
Leerink Partners Maintains Buy on Gilead Sciences (GILD)
Sep 7, 2025 • Yahoo Finance
Gilead Sciences advances HIV prevention with new US partnership
Sep 5, 2025 • Pharmaceutical Technology
Gilead Sciences Breaks Ground on New Biomanufacturing Hub
Sep 5, 2025 • Genetic Engineering and Biotechnology News
Gilead Sciences sets $32bn plan for AI-geared pharma factories in the US
Sep 5, 2025 • RCR Wireless News
Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV
Sep 4, 2025 • Business Wire
Gilead urges people living with HIV to 'Choose U' in campaign touting long-term treatment success
Sep 4, 2025 • Fierce Pharma
Gilead Sciences breaks ground on new manufacturing hub
Sep 4, 2025 • The Pharma Letter
US plans to bring Gilead HIV drug to market in high-burden HIV countries
Sep 4, 2025 • Reuters
Department of State, Gilead Sciences, and The Global Fund Announcement of Lifesaving and Innovative PEPFAR Initiative
Sep 4, 2025 • U.S. Department of State (.gov)